MTOR and breast carcinoma: In one report, however, which assessed seven estrogen receptor (ER)-positive breast cancer cell lines and their response to the allosteric mTOR inhibitor Rapamycin (Sirolimus), no correlation with PIK3CA mutation status but to some extent with a PIK3CA mutation associated gene signature was found (Loi et al., 2010).